纯度 | >95%SDS-PAGE. |
种属 | Human |
靶点 | OLR1 / LOX1 |
Uniprot No | P78380 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 61-273aa |
氨基酸序列 | SQVSDLLTQEQANLTHQKKKLEGQISARQQAEEASQESENELKEMIETLA RKLNEKSKEQMELHHQNLNLQETLKRVANCSAPCPQDWIWHGENCYLFSS GSFNWEKSQEKCLSLDAKLLKINSTADLDFIQQAISYSSFPFWMGLSRRN PSYPWLWEDGSPLMPHLFRVRGAVSQTYPSGTCAYIQRGAVYAENCILAA FSICQKKANLRAQVDHHHHHH |
预测分子量 | 25 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于OLR1/LOX1重组蛋白的3篇参考文献及其摘要概括:
1. **《LOX-1 in atherosclerosis: biological functions and pharmacological modifiers》**
- 作者:T. Sawamura, N. Kume
- 摘要:该综述探讨了LOX-1作为氧化低密度脂蛋白受体的生物学功能,并提到通过重组LOX-1蛋白研究其在动脉粥样硬化中的作用,包括炎症和细胞凋亡机制。
2. **《Recombinant lectin-like oxidized LDL receptor 1 (LOX-1) induces endothelial dysfunction and inflammatory response in vitro》**
- 作者:Y. Chen 等
- 摘要:研究利用重组LOX-1蛋白证明其与氧化LDL结合后,可诱导内皮细胞炎症因子表达和氧化应激反应,提示其在心血管疾病中的病理作用。
3. **《Expression and functional characterization of recombinant human LOX-1 in mammalian cells》**
- 作者:K. Oka 等
- 摘要:该文献描述了在哺乳动物细胞中成功表达并纯化重组人LOX-1蛋白,验证其与氧化LDL的结合能力及在泡沫细胞形成中的功能,为药物靶点研究提供工具。
注:若需具体文献来源(期刊、年份等),可进一步提供关键词或数据库检索支持。
**Background of OLR1/LOX-1 Recombinant Protein**
OLR1 (Oxidized Low-Density Lipoprotein Receptor 1), also known as LOX-1. is a scavenger receptor primarily involved in recognizing and binding oxidized low-density lipoprotein (oxLDL), a key player in atherosclerosis. Discovered in 1997. LOX-1 is a type II transmembrane glycoprotein belonging to the C-type lectin receptor family. Structurally, it consists of a short N-terminal cytoplasmic domain, a transmembrane region, a neck domain, and a C-terminal lectin-like ligand-binding domain. LOX-1 is predominantly expressed in vascular endothelial cells, macrophages, and smooth muscle cells, though its expression can be induced in other cell types under inflammatory or oxidative stress conditions.
LOX-1 mediates the uptake of oxLDL, contributing to foam cell formation, endothelial dysfunction, and plaque instability in cardiovascular diseases. Beyond lipid metabolism, it participates in pro-inflammatory and pro-apoptotic signaling pathways, interacting with ligands like advanced glycation end products (AGEs), apoptotic cells, and pathogens. Dysregulation of LOX-1 is linked to atherosclerosis, hypertension, diabetes, and ischemic injury, making it a therapeutic target.
Recombinant LOX-1 proteins are engineered to study its structure, ligand interactions, and downstream signaling. Produced via heterologous expression systems (e.g., mammalian, insect, or bacterial cells), these proteins retain functional domains for in vitro and in vivo studies. Recombinant LOX-1 facilitates drug discovery by screening inhibitors, validating antibodies, or modeling receptor-ligand dynamics. It also aids in elucidating pathological mechanisms and developing diagnostic or therapeutic strategies targeting LOX-1-mediated pathways.
Overall, LOX-1 recombinant proteins serve as critical tools in cardiovascular research, bridging molecular insights to potential clinical applications.
×